Subscribe to our mailing list

AbbVie, going through fits over testosterone complement, will get a major win

CHICAGO — AbbVie notched a win final month in its ongoing battle towards 1000’s of lawsuits that declare AndroGel, a once-blockbuster drug marketed to deal with low testosterone in males, causes coronary heart assaults, strokes and different accidents.

A jury determined that the drugmaker was to not blame for the pulmonary embolism suffered by an Arizona retiree who began utilizing AndroGel after seeing TV commercials selling testosterone remedy as a repair for fatigue and low intercourse drive. It marked the primary verdict in federal courtroom in Chicago, the place AbbVie is predicated, to clear the corporate of any wrongdoing.

Powered by WPeMatico

Author: Techno Info

VN:F [1.9.22_1171]
Rating: 0.0/10 (0 votes cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)

Author Spotlight